Glasgow, SCOTLAND. Sistemic Ltd. announced today that it had signed an agreement with Roslin Cells Ltd. to analyse iPSC (induced Pluripotent Stem Cell) samples from 7 of Europe’s leading centres for iPSC production.
As part of an Innovative Medicines Initiative Programme to establish the European Bank for induced pluripotent Stem Cells (EBiSC). The EBiSC programme is a pan-European, multicentre programme co-ordinated by Pfizer Ltd and managed by Roslin Cells which will accept deposits of iPSCs from across Europe to create a diverse collection of well characterised iPS cell lines for a range of research activities including drug discovery.
Jim Reid, CEO of Sistemic said “We are immensely excited by this collaboration. The potential for well characterised iPSC’s is almost without limit and the EBiSC programme will undoubtedly move research in the field forward significantly. The ability to have large quantities of standardised and well characterised iPS cell lines available for research will be a significant boost for the wide range of academic and industrial research groups interested in working in this area and will undoubtedly contribute to more efficient drug development. We are also delighted that the managing partner, Roslin Cells, has decided, following extensive discussion and diligence, to use the Sistemic SistemQC™ technology as part of their characterisation effort. This is a major break-through for Sistemic and we are delighted to be part of this significant European initiative.”
Aidan Courtney, CEO of Roslin Cells said “Sistemic’s expertise and technology has great potential for the EBiSC programme. Our goal for EBiSC is to enable researchers around the world to have ready access to high quality and well characterised stocks of human iPS cells. These will be used in research to understand better the causes of diseases such as Parkinson’s, Alzheimer’s and Diabetes through the creation of novel, non-animal based models. As well as advancing basic research, this will support the development of a wide range of pharmaceutical drug discovery programmes. Sistemic’s expertise in microRNA profiling will allow us to develop more cost effective readouts of the stem cells’ potential for differentiating into cells of specific lineages such as nerve, heart and liver cells.”
For more information contact: email@example.com
Sistemic’s primary business is focused on providing innovative microRNA-based problem-solving services and kit-based products to areas of unmet need within Pharmaceutical, Biotechnology and the Cell Therapy research, development and manufacture markets.
MicroRNAs are seen as the master controllers of a cell and as such Sistemic believe that they are providing instructive information on effects on a whole cell or organism rather than an isolated pathway. This system approach means that the data produced is more indicative of the biology and more diagnostic of actual effect. Their extensive suite of tools for the Cell Therapy community includes SistemQC™ which is used to characterise cells including stem cells (Cell Identity, Purity, Potency, and Safety) as well as monitoring the QC of production. Furthermore, cell products in the later stages of clinical development benefit from SistemQC™ miRNA-based profiling approach in facilitating patient stratification and monitoring the response to the treatment. In addition, the drug development markets are served through a range of products which include SistemTOX™ , SistemKB™ and SistemRNA™ . Sistemic has a worldwide customer base and a strong intellectual property portfolio.
About Roslin Cells
Roslin Cells is a leader in the development of cell therapies and provides Good Manufacturing Practice (GMP) manufacturing services for cell therapy products and mammalian cell banks for clinical use. Roslin Cells also provides a range of pluripotent stem cells for clinical use and research customers.
Roslin Cells was spun out of the world renowned Roslin Institute in 2006, through funding from Scottish Enterprise. Now based at the Edinburgh BioQuarter within the Scottish Centre for Regenerative Medicine (SCRM), the Company operates a state of‐ the‐art, seven clean room GMP Cellular Therapy manufacturing facility in partnership with the Scottish National Blood Transfusion Service (SNBTS). Roslin Cells supports its clients to the clinic by providing full process development and translational capabilities including early phase GMP manufacturing of cellular therapies for clinical trials.
The Company has a suite of development laboratories within the neighbouring Nine BioQuarter building, including an induced pluripotent stem cell (iPSC) facility. Roslin Cells is the only UK company providing research and clinical grade iPSC services to prominent industry, academic and clinical researchers who are breaking new ground in cellular models for research, drug discovery and the next generation of cells to be manufactured for cellular therapies.